Presurgical octreotide treatment in acromegaly: No improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study

Acta Neurochirurgica

Volumn 147, Issue 5, 2005, Pages 485-493

  Plockinger U ^a   Quabbe, H J ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Acromegaly; Octreotide pretreatment; Pituitary function; Surgery

Indexed keywords

CHENODEOXYCHOLIC ACID; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; URSODEOXYCHOLIC ACID;

ACROMEGALY; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCRINE DISEASE; FEMALE; GALLBLADDER DISEASE; GALLSTONE; GASTROINTESTINAL SYMPTOM; GLUCOSE TOLERANCE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS ADRENAL SYSTEM; HYPOPHYSIS FUNCTION; MALE; NEUROIMAGING; NEUROSURGERY; ORAL GLUCOSE TOLERANCE TEST; PATIENT SELECTION; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; STANDARDIZATION; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; GROWTH HORMONE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; OCTREOTIDE; PITUITARY GLAND; PITUITARY HORMONES, ANTERIOR; PITUITARY NEOPLASMS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TIME; TREATMENT OUTCOME;

EID: 18044373876     PISSN: 00016268     EISSN: 09420940     Source Type: Journal    
DOI: 10.1007/s00701-005-0511-9     Document Type: Article

References (40)

1. Abe T, Lüdecke DK (2001) Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical center. Eur J Endocrinol 145: 137-145
2. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83: 3411-3418
3. Achenbach K, Oelkers W (1985) Comparison of insulin hypoglycemia and short metyrapone tests in patients with pituitary disease. Klin Wschr 63: 769-774
4. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA (1999) Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol 50: 561-567
5. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67: 1040-1048
6. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87: 4554-4563
7. Biermasz NR, van Dulken H, Roelfsema F (1999) Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 84: 3551-3555
8. Colao A, Ferone D, Cappabianca P, Del Basso de Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, De Divitiis E, Lombardi G (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82: 3308-3314
9. Davis DH, Laws ER, Ilstrup DM, Speed JK, Caruso M, Shaw EG (1993) Results of surgical treatment for growth hormone-secreting pituitary adenomas. J Neurosurg 79: 70-75
10. Ducasse MCR, Tauber JP, Tourre A, Bonafe A, Babin T, Tauber MT, Harris AG, Bayard F (1987) Shrinking of a growth hormone-producing pituitary tumour by continuous subcutaneous infusion of the somatostatin analog SMS 201-995. J Clin Endocrinol Metab 65: 1042-1046
11. Fahlbusch R, Honegger J, Buchfelder M (1992) Surgical management of acromegaly. In: Melmed S (ed) Acromegaly. Endocrinology and Metabolism Clinics of North America, vol 21(3). WB Saunders, Philadelphia, pp 669-692
12. Freda PA (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87: 3013-3018
13. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85: 526-529
14. Ho KY, Weissberger AJ, Marbach P, Lazarus L (1990) Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. Ann Intern Med 112: 159-160
15. Ikeda H, Jokura H, Yoshimoto T (2001) Transsphenoidal surgery and adjuvant gamma knife treatment for growth hormone-secreting pituitary adenoma. J Neurosurg 95: 285-291
16. Jenkins D, O'Brien I, Johnson A, Shakespear R, Sheppard MC, Stewart PM (1995) The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clin Endocrinol 43: 517-522
17. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F (2001) Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 86: 1645-1652
18. Kreutzer J, Vance ML, Lopes MBS, Laws ER (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86: 4072-4077
19. Kristof RA, Stoffel-Wagner B, Klingmüller D, Schramm J (1999) Does octreotide treatment improve the surgical results of macroadenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 141: 399-405
20. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JRE, Shalet SM (1998) The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol 49: 653-657
21. Lucas-Morante T, García-Uría J, Estrada J, Saucedo G, Cabello A, Alcañiz J, Barcelo B (1994) Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 81: 10-14
22. Lundin P, Pedersen F (1992) Volume of pituitary macroadenomas: assessment by MRI. J Comp Ass Tomography 16: 519-528
23. McKeage K, Cheer S, Wagstaff AJ (2003) Octreotide long-acting release (LAR). A review of its use in the management of acromegaly. Drugs 63: 2473-2499
24. Meij BP, Lopes M-BS, Ellegala DB, Alden TD, Laws ER Jr (2002) The long-term significance of microscopic durai invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96: 195-208
25. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M (1995) Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 80: 3395-3402
26. Melmed S, Vance ML, Barkan AL, Bengtsson BA, Kleinberg D, Klibanski A, Trainer PJ (2002) Current status and future opportunities for controlling acromegaly. Pituitary 5: 185-196
27. Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Moroni C, Lenzi J, Tamburrano G, Cassone R, Cantore G (2001) Surgical treatment and clinical outcome of GH-secreting adenomas in elderly patients. Acta Neurochir (Wien) 143: 1205-1211
28. Osman IA, James RA, Chatterjee S, Mathias D, Kendall-Taylor P (1994) Factors determining the long-term outcome of surgery for acromegaly. Q J Med 87: 617-623
29. Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe H-J (1994) Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumour volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 79: 1416-1423
30. Quabbe H-J (1982) Treatment of acromegaly by transsphenoidal operation, 90-Yttrium implantation and bromocriptine: results in 230 patients. Clin Endocrinol 16: 107-119
31. Seidman PA, Kofke WA, Policare R, Young M (2000) Anaesthetic complications of acromegaly. Br J Anaesth 2: 179-182
32. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JAH (1996) Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 45: 407-413
33. Sheppard MC (2000) Follow-up of treated acromegaly: similarities and differences in assessing the response to different primary treatment modalities. Growth Horm IGF Res [Suppl B]: S115-S118
34. Shimon I, Cohen ZR, Ram Z, Hadani M (2001) Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurg 48: 1239-1245
35. Stevenaert A, Beckers A (1996) Presurgical octreotide: treatment in acromegaly. Metabolism 45 [Suppl 1]: 72-74
36. Swearingen B, Barker II FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, Moayeri N, Black PMCL, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83: 3419-3426
37. Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA (1993) Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg 78: 205-215
38. WHO Expert Committee on Diabetes mellitus (1980) Technical Report Series 646. WHO, Geneva, pp 8-14
39. Wilson CB (1984) A decade of pituitary microsurgery. J Neurosurg 61: 814-833
40. Yamada S, Aiba T, Takada K, Ozawa Y, Shimizu T, Sawano S, Shishiba Y, Sano T (1996) Retrospective analysis of long-term surgical results in acromegaly: preoperative and postoperative factors predicting outcome. Clin Endocrinol 45: 291-298